Trump May Look to Advance International Pricing Index

Game On: Groups Launch Competing Drug Pricing Ad Campaigns  With prospects dim, at least in the short-term, for passage of comprehensive drug pricing legislation in Congress, some Washington observers suggest President Trump is eager to push for regulatory changes in an effort to capture the high ground on lowering prescription drug costs ahead of the […]

Read More

Speakers, Agenda Announced for 2020 Entrepreneur & Investor Life Science Summit

BioUtah/TVC 2020 Entrepreneur & Investor Life Science Summit Salt Lake City, Utah – January 17, 2020 – BioUtah, Utah’s only trade association dedicated solely to the life sciences, along with the Center for Technology & Venture Commercialization at the University of Utah, today announced distinguished speakers and sessions for the 2020 Entrepreneur & Investor Life […]

Read More

Antibiotic-Resistant “Superbugs” – Public Health Crisis and Research Challenge

Antimicrobial Resistance (AMR) is a public health crisis, but developing new classes of antibiotics to combat drug resistant bacteria is challenging on many levels. Last month, the New York Times reported on the struggles facing companies that are researching new antibiotics. In November, the Centers for Disease Control and Prevention (CDC) released a report, Antibiotic Resistance […]

Read More

Positioning on Drug Pricing Continues

Sen. Grassley Calls on Pelosi to Support His Bill Conservative Group Backs GOP Drug Pricing Alternative As we head into 2020 election season, Democrats and Republicans alike will be working to convince voters that they have the right “prescription” to lower drug costs. At present, several different approaches are circling. With the passage of H.R. […]

Read More

Red Tape Reduction: FDA Issues List of 510(k) Device Exemptions

On December 30, the FDA issued a notice (see the FDA’s Federal Register notice)  that exempts certain class I and II medical devices from 510(k) premarket notification requirements. The exemptions, some of which are limited, cover a wide range of different products, including clinical chemistry test systems, clinical laboratory instruments, clinical toxicology test systems, hematology […]

Read More

Congress Reconvenes: Drug Pricing, USMCA updates

Congress returned yesterday with a number of big ticket items on their plate, including drug pricing and the U.S.-Mexico-Canada Agreement (USMCA), both of which have implications for Utah’s life sciences industry. Drug Pricing As the House of Representatives was passing the Democrat drug pricing plan, H.R. 3, the Lower Drug Prices Now Act, in the […]

Read More